BP-2201

N/A

Report date: 2024/08/02 15:30:42

Base Information

Drug NameBP-2201
Drug Alias NameBP-2201BP2201
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cell replacements
TargetsNot applicable
Therapy Area/IndicationsHead and Neck Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesBrightpath Biotherapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBrightpath Biotherapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsHead and Neck Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A